ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
about
Breast cancer stem-like cells: clinical implications and therapeutic strategiesAldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumorsComparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.Aldehyde dehydrogenase 1 expression is correlated with poor prognosis in breast cancerAldehyde dehydrogenase 1 expression correlates with clinicopathologic features of patients with breast cancer: a meta-analysisSelective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases.Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis.ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer.Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.Distinct prognostic values of ALDH1 isoenzymes in breast cancer.Associations between ALDH1A1 polymorphisms, alcohol consumption, and mortality among Hispanic and non-Hispanic white women diagnosed with breast cancer: the Breast Cancer Health Disparities Study.Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent.Quercetin Inhibits Breast Cancer Stem Cells via Downregulation of Aldehyde Dehydrogenase 1A1 (ALDH1A1), Chemokine Receptor Type 4 (CXCR4), Mucin 1 (MUC1), and Epithelial Cell Adhesion Molecule (EpCAM).Aldehyde dehydrogenase 1 as a predictor of the neoadjuvant chemotherapy response in breast cancer: A meta-analysis
P2860
Q26752170-EF461266-4A33-46A1-9EED-5AAA687803CAQ26786476-AD117980-21C4-40B2-B52B-FE1B83D45522Q33674656-329F4A41-49D8-4661-9448-C88F72C40E87Q33833666-6FA21991-0EC7-41A4-9BD8-88D4B9ADCA5EQ35958671-3B8BE3AB-A670-4703-9E57-9F5F644C7A29Q36031339-A7B79ABD-430B-46BD-8073-D108C54311D3Q36170933-1EA39E84-8FF6-493C-85D4-1CE454928606Q36256977-9BCDDDBF-A8CC-458F-ADC5-B46674F4F814Q36562382-556A2F2C-589F-4797-8204-14DE1FD92D53Q37059543-038AECD9-02D9-47D4-867D-ACF1A5075804Q41591538-998DCDED-3E5C-4AC0-95C9-E16164636CB2Q46409708-ED53682A-FD8B-4C63-B59D-DAAA1E181217Q48158656-31251CCB-839E-43C6-9300-E9C24FCEAD0FQ49810281-454FBD45-F0EF-47ED-82CC-CB7E492202A4Q57108835-F015E237-D140-486B-BC8C-A0DF3B723192
P2860
ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@en
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@nl
type
label
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@en
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@nl
prefLabel
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@en
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@nl
P2093
P2860
P1433
P1476
ALDH1 is a better clinical ind ...... han the CD44+/CD24- phenotype.
@en
P2093
Jinghong Guan
Songjie Shen
Yidong Zhou
Ying Zhong
P2860
P2888
P356
10.1007/S12032-014-0864-0
P577
2014-02-12T00:00:00Z